keyword
MENU ▼
Read by QxMD icon Read
search

Valsartan with amlodipine

keyword
https://www.readbyqxmd.com/read/29781736/comparison-of-real-world-effectiveness-between-valsartan-and-non-ras-inhibitor-monotherapy-on-the-incidence-of-new-diabetes-in-chinese-hypertensive-patients-an-electronic-health-recording-system-based-study
#1
Tian Shen, Jiwei Wang, Yingjun Yu, Jinming Yu
This study aimed to compare the real-world effectiveness of valsartan and non renin-angiotensin system (non-RAS) agent monotherapy on the incidence of new on-set diabetes (NOD) in Chinese hypertensive patients. It was based on an electronic Health Recording System database from Minhang District of Shanghai. Hypertensive patients aged ≥18 years continuously taking either valsartan or non-RAS agent monotherapy for >12 months were included. Hazard ratios (HR) of NOD events were estimated using propensity score matching method and multivariate regression...
May 21, 2018: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/29674000/angiotensin-ii-promotes-pulmonary-metastasis-of-melanoma-through-the-activation-of-adhesion-molecules-in-vascular-endothelial-cells
#2
Shin Ishikane, Hiroshi Hosoda, Takashi Nojiri, Takeshi Tokudome, Tetsuya Mizutani, Koichi Miura, Yoshiharu Akitake, Toru Kimura, Yoshitaka Imamichi, Shinya Kawabe, Yumiko Toyohira, Nobuyuki Yanagihara, Fumi Takahashi-Yanaga, Mikiya Miyazato, Kaoru Miyamoto, Kenji Kangawa
Hypertension is considered as one of the cancer progressive factors, and often found comorbidity in cancer patients. Renin-angiotensin system (RAS) plays an important role in the regulation of blood pressure, and angiotensin II (Ang II) is well known pressor peptide associated with RAS. Ang II has been reported to accelerate progression and metastasis of cancer cells. However, its precise mechanisms have not been fully understood. In this study, we sought to elucidate the mechanisms by which Ang II exacerbates hematogenous metastasis in mouse melanoma cells, focusing the adhesion pathway in vascular endothelial cells...
April 17, 2018: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29604332/effects-of-hydrochlorothiazide-and-amlodipine-on-single-oral-dose-pharmacokinetics-of-valsartan-in-healthy-korean-subjects-population-model-based-approach
#3
Lien Ngo, Hea-Young Cho, Yong-Bok Lee
Fixed dose combination (FDC) of valsartan (VAL) and hydrochlorothiazide (HCT) or VAL and amlodipine (AML) has been available in many countries for the treatment of hypertension. Due to drug-drug interaction potentials, in the current study we aimed to evaluate potent effects of HCT and AML on pharmacokinetics (PKs) of VAL when they are orally co-administered as FDC (VAL/HCT at 80/12.5 mg or 160/12.5 mg; and VAL/AML at 160/5 mg or 160/10 mg) products in healthy Korean subjects. Population pharmacokinetic (PK) modeling and analysis were performed by the nonlinear mixed-effects modeling software...
March 28, 2018: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29365085/blood-pressure-variability-and-risk-of-cardiovascular-events-and-death-in-patients-with-hypertension-and-different-baseline-risks
#4
Maria H Mehlum, Knut Liestøl, Sverre E Kjeldsen, Stevo Julius, Tsushung A Hua, Peter M Rothwell, Giuseppe Mancia, Gianfranco Parati, Michael A Weber, Eivind Berge
Aims: Blood pressure variability is associated with increased risk of cardiovascular events, particularly in high-risk patients. We assessed if variability was associated with increased risk of cardiovascular events and death in hypertensive patients at different risk levels. Methods and results: The Valsartan Antihypertensive Long-term Use Evaluation trial was a randomized controlled trial of valsartan vs. amlodipine in patients with hypertension and different risks of cardiovascular events, followed for a mean of 4...
January 20, 2018: European Heart Journal
https://www.readbyqxmd.com/read/29210288/efficacy-and-effectiveness-of-valsartan-amlodipine-and-valsartan-amlodipine-hydrochlorothiazide-in-hypertension-randomized-controlled-versus-observational-studies
#5
Jorge Sison, Rosa María Ríos Vega, Hu Dayi, Giovanni Bader, Patrick Brunel
OBJECTIVE: The aim of this post-hoc analysis was to compare the results from randomized controlled trials (RCTs) and real-world evidence (RWE) studies of valsartan/amlodipine (Val/Aml) and valsartan/amlodipine/hydrochlorothiazide (Val/Aml/HCTZ) in patients with uncontrolled hypertension (>140/90 mmHg). METHODS: Data was pooled from 15 RCTs (N = 5542) and 8 RWE studies (N = 1397) for Val/Aml; and 2 RCTs (N = 804) and 5 RWE studies (N = 9380) for Val/Aml/HCTZ...
March 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29180454/effect-of-sacubitril-valsartan-on-exercise-induced-lipid-metabolism-in-patients-with-obesity-and-hypertension
#6
RANDOMIZED CONTROLLED TRIAL
Stefan Engeli, Rudi Stinkens, Tim Heise, Marcus May, Gijs H Goossens, Ellen E Blaak, Bas Havekes, Thomas Jax, Diego Albrecht, Parasar Pal, Uwe Tegtbur, Sven Haufe, Thomas H Langenickel, Jens Jordan
Sacubitril/valsartan (LCZ696), a novel angiotensin receptor-neprilysin inhibitor, was recently approved for the treatment of heart failure with reduced ejection fraction. Neprilysin degrades several peptides that modulate lipid metabolism, including natriuretic peptides. In this study, we investigated the effects of 8 weeks' treatment with sacubitril/valsartan on whole-body and adipose tissue lipolysis and lipid oxidation during defined physical exercise compared with the metabolically neutral comparator amlodipine...
January 2018: Hypertension
https://www.readbyqxmd.com/read/29106031/comparison-of-morning-vs-bedtime-administration-of-the-combination-of-valsartan-amlodipine-on-nocturnal-brachial-and-central-blood-pressure-in-patients-with-hypertension
#7
Takeshi Fujiwara, Satoshi Hoshide, Yuichiro Yano, Hiroshi Kanegae, Kazuomi Kario
The aim of this study was to compare the effect of morning and bedtime administration of valsartan/amlodipine combination therapy (80/5 mg) on nocturnal brachial and central blood pressure (BP) measured by ambulatory BP monitoring in patients with hypertension. This was a 16-week prospective, multicenter, randomized, open-label, crossover, noninferiority clinical trial. Patients underwent 24-hour ambulatory BP monitoring at randomization, at switching, and at the end of the study. Twenty-three patients (mean age, 68...
December 2017: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29105958/additivity-of-nebivolol-valsartan-single-pill-combinations-versus-other-single-pill-combinations-for-hypertension
#8
Jack Ishak, Michael Rael, Henry Punzi, Alan Gradman, Lynn M Anderson, Mehul Patel, Sanjida Ali, William Ferguson, Joel Neutel
The single-pill combination (SPC) comprising nebivolol (5 mg), a vasodilatory β1 -selective antagonist/β3 -agonist, and valsartan (80 mg), a renin-angiotensin-aldosterone system inhibitor, is the only Food and Drug Administration-approved β-blocker/renin-angiotensin-aldosterone system inhibitor SPC for hypertension. Additive effects of four nebivolol/valsartan SPC doses (5 mg/80 mg, 5/160 mg, 10/160 mg, 10/320 mg nebivolol/valsartan) were compared with five Food and Drug Administration-approved non-β-blocker/renin-angiotensin-aldosterone system inhibitor SPCs (aliskiren/hydrochlorothiazide, aliskiren/amlodipine, valsartan/amlodipine, aliskiren/valsartan, and telmisartan/amlodipine)...
January 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/28721135/a-comprehensive-guidelines-based-approach-reduces-cardiovascular-risk-in-everyday-practice-the-varo-study
#9
Tomáš Štulc, Věra Lánská, Michaela Šnejdrlová, Michal Vrablík, Martina Prusíková, Richard Češka
INTRODUCTION: The aim of study was to investigate the possibility of cardiovascular risk improvement through systematic identification of high-risk individuals and treatment in accordance with current guidelines using modern therapy in daily clinical practice. MATERIAL AND METHODS: Two hundred and sixty-three physicians participated in the study. The physicians were asked to screen for cardiovascular risk factors in patients presenting with unrelated problems and to re-evaluate the attainment of treatment goals in those with already known risk factors...
June 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28666228/high-throughput-quantification-of-8-antihypertensive-drugs-and-active-metabolites-in-human-plasma-using-uplc-ms-ms
#10
Bart C H van der Nagel, Jorie Versmissen, Soma Bahmany, Teun van Gelder, Birgit C P Koch
BACKGROUND: To assess drug adherence of patients with hypertension, an analytical method was developed and validated using ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). The method includes eight frequently prescribed antihypertensive drugs from four classes and their active metabolites: angiotensin converting enzyme inhibitors enalapril and perindopril (active metabolites respectively enalaprilate and perindoprilate), angiotensin II receptor blockers losartan (with the active metabolite losartan carboxylic acid) and valsartan, calcium channel blockers amlodipine and nifedipine and diuretics hydrochlorothiazide and spironolactone (with the active metabolite canrenone)...
August 15, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/28665713/mrna-levels-of-circadian-clock-components-bmal1-and-per2-alter-independently-from-dosing-time-dependent-efficacy-of-combination-treatment-with-valsartan-and-amlodipine-in-spontaneously-hypertensive-rats
#11
Peter Potucek, Michal Radik, Gabriel Doka, Eva Kralova, Peter Krenek, Jan Klimas
Chronopharmacological effects of antihypertensives play a role in the outcome of hypertension therapy. However, studies produce contradictory findings when combination of valsartan plus amlodipine (VA) is applied. Here, we hypothesized different efficacy of morning versus evening dosing of VA in spontaneously hypertensive rats (SHR) and the involvement of circadian clock genes Bmal1 and Per2. We tested the therapy outcome in short-term and also long-term settings. SHRs aged between 8 and 10 weeks were treated with 10 mg/kg of valsartan and 4 mg/kg of amlodipine, either in the morning or in the evening with treatment duration 1 or 6 weeks and compared with parallel placebo groups...
June 30, 2017: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/28658108/effectiveness-and-safety-of-valsartan-amlodipine-in-hypertensive-patients-with-stroke-china-status-ii-subanalysis
#12
MULTICENTER STUDY
Weiliang Zhang, Yongbin Song, Jiangtao Xu
High blood pressure (BP) is a major risk factor associated with stroke in China. This is a subanalysis of patients from the China Status II study, aimed to evaluate the effectiveness and safety of valsartan/amlodipine (Val/Aml) single-pill combination (SPC) in hypertensive patients with different stroke subtypes (hemorrhagic, ischemic, or mixed).China Status II was a multicenter, postmarketing, prospective observational study in hypertensive patients uncontrolled on monotherapy. The study was an 8-week open-label treatment period with 2 4-week follow-ups...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28562571/hemodynamic-instability-after-pulmonary-veins-isolation-in-a-patient-with-dual-chamber-pacemaker-the-phantom-injury-of-the-ventricular-lead
#13
Márcio Galindo Kiuchi, Guilherme Miglioli Lobato, Shaojie Chen
INTRODUCTION: The standard treatment of sinus node dysfunction (SND) is the pacemaker implantation, and the ideal methodology for the management of atrial fibrillation (AF) is rhythm control, but this is sometimes very hard to accomplish. For such actions, complete isolation of all pulmonary veins (PVI) is currently widely accepted as the best endpoint. CASE PRESENTATION: In this case, we report a female patient, 81 years old, with controlled hypertension, without coronary artery disease, bearer of bilateral knee replacement, and dual chamber pacemaker implanted 1...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28527109/erratum-to-clinical-pharmacokinetics-of-sacubitril-valsartan-lcz696-a-novel-angiotensin-receptor-neprilysin-inhibitor
#14
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu, Gangadhar Sunkara
Sacubitril/valsartan (LCZ696) is indicated for the treatment of heart failure with reduced ejection fraction. Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, 1.5-2.0, and 2.0-3.0 h, respectively. With a twofold increase in dose, an increase in the area under the plasma concentration-time curve was proportional for sacubitril, ~1...
January 2018: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28490725/effects-of-valsartan-and-amlodipine-on-oxidative-stress-in-type-2-diabetic-patients-with-hypertension-a-randomized-multicenter-study
#15
Hae Jin Kim, Seung Jin Han, Dae Jung Kim, Hak Chul Jang, Soo Lim, Sung Hee Choi, Yong Hyun Kim, Dong Hyun Shin, Se Hwa Kim, Tae Ho Kim, Yu Bae Ahn, Seung Hyun Ko, Nan Hee Kim, Ji A Seo, Ha Young Kim, Kwan Woo Lee
BACKGROUND/AIMS: Oxidative stress plays an important role in the pathogenesis and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress. In this study, we compared the changes in oxidative stress markers after valsartan and amlodipine treatment in type 2 diabetic patients with hypertension and compared the changes in metabolic parameters. METHODS: Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks...
May 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28417439/clinical-pharmacokinetics-of-sacubitril-valsartan-lcz696-a-novel-angiotensin-receptor-neprilysin-inhibitor
#16
REVIEW
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu, Gangadhar Sunkara
Sacubitril/valsartan (LCZ696) is indicated for the treatment of heart failure with reduced ejection fraction. Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, 1.5-2.0, and 2.0-3.0 h, respectively. With a two-fold increase in dose, an increase in the area under the plasma concentration-time curve was proportional for sacubitril, ~1...
December 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28340729/development-validation-and-comparison-of-near-infrared-and-raman-spectroscopic-methods-for-fast-characterization-of-tablets-with-amlodipine-and-valsartan
#17
Tibor Casian, Andra Reznek, Andreea Loredana Vonica-Gligor, Jeroen Van Renterghem, Thomas De Beer, Ioan Tomuță
The objective of this study was to develop, validate and compare NIR and Raman spectroscopic methods for fast characterization in terms of API content and tensile strength of fixed-dose combination tablets containing amlodipine and valsartan. For the APIs assay NIR-transmittance and Raman-reflectance methods were considered, whereas for the tensile strength assay Raman spectra were recorded in reflectance configuration and NIR spectra were recorded in both reflectance and transmittance. Multivariate calibration models (PLS) were built by applying different pre-processing methods (SNV, MSC, SD+SNV) on certain spectral regions...
May 15, 2017: Talanta
https://www.readbyqxmd.com/read/28230062/triple-combination-therapy-in-the-treatment-of-hypertension-a-review-of-the-evidence
#18
REVIEW
R Düsing, B Waeber, M Destro, C Santos Maia, P Brunel
Hypertension is a serious public health concern with inadequate control of blood pressure (BP) worldwide. Contributing factors include low efficacy of drugs, underuse of combination therapies, irrational combinations, physicians' therapeutic inertia and poor adherence to treatment. Current guidelines recommend the use of initial (dual) combination therapy in high-risk patients for immediate BP response, better short- and long-term BP control, and continued/improved patient adherence. This article aims to review the existing evidence of triple-combination therapies with respect to efficacy, safety and adherence to treatment...
August 2017: Journal of Human Hypertension
https://www.readbyqxmd.com/read/28104105/effects-of-amlodipine-and-valsartan-on-blood-pressure-variability-and-pulse-wave-velocity-in-hypertensive-patients
#19
RANDOMIZED CONTROLLED TRIAL
Rufeng Shi, Kai Liu, Di Shi, Qi Liu, Xiaoping Chen
OBJECTIVES: Antihypertensive therapy is effective to control blood pressure (BP) and to prevent cardiovascular events, but the further treatment strategies for patients who cannot achieve goal BP with low-dose monotherapy is still under dispute. Our study investigates the effects of high-dose amlodipine and valsartan and their low-dose combination on blood pressure variability (BPV) and pulse wave velocity (PWV) to provide references for clinical medication. MATERIALS AND METHODS: This study was a prospective, randomized, parallel, case-controlled trial performed in a medical center...
January 2017: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/28093466/effects-of-sacubitril-valsartan-versus-olmesartan-on-central-hemodynamics-in-the-elderly-with-systolic-hypertension-the-parameter-study
#20
RANDOMIZED CONTROLLED TRIAL
Bryan Williams, John R Cockcroft, Kazuomi Kario, Dion H Zappe, Patrick C Brunel, Qian Wang, Weinong Guo
Effective treatment of systolic hypertension in elderly patients remains a major therapeutic challenge. A multicenter, double-blind, randomized controlled trial with sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, was conducted to determine its effects versus olmesartan (angiotensin receptor blocker) on central aortic pressures, in elderly patients (aged ≥60 years) with systolic hypertension and pulse pressure >60 mm Hg, indicative of arterial stiffness. Patients (n=454; mean age, 67...
March 2017: Hypertension
keyword
keyword
83478
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"